211 800 0071


Καθημερινά 10:00 έως 17:00

Βουτσινά Αλεξάνδρα – Βιολογία ιδιαίτερα μαθήματα

Βουτσινά Αλεξάνδρα – Βιολογία

Περιοχή κατοικίας: Αθήνα-κέντρο

Online μαθήματα: Ναι


Παιδιά Φοιτητές Ενήλικες

Μαθητές με μαθησιακές δυσκολίες










Βασικός Τίτλος Σπουδών


Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών

Τμήμα Βιολογίας

Μεταπτυχιακός Τίτλος Σπουδών

Το σύστημα ελέγχου βιοσύνθεσης των αμινοξέων στο Σχιζοσακαχαρομύκητα

Διδακτορικός Τίτλος Σπουδών

Δομική και λειτουργική ανάλυση της κοινής υπομονάδας των RNA πολυμερασών Rpb8

Διδακτική Πείρα στα Ιδιαίτερα Μαθήματα Βιολογίας

1. Διδασκαλία μαθήματος "Γενετική" στο ΤΕΙ ΗΡΑΚΛΕΙΟΥ

2. Διδασκαλία μαθημάτων σύμφωνα με τις διατάξεις ΠΔ407

3. Διδασκαλία "Βιοχημείας" στα ΙΕΚ ΗΡΑΚΛΕΙΟΥ

4. Διδασκαλία Βιολογίας στη Δευτεροβάθμια Εκπαίδευση από το 2009

Σεμινάρια - Επιμόρφωση

Ετήσιο Σεμινάριο: Εξειδίκευση στην ειδική αγωγή και τεχνολογίες πληροφορικής και επικοινωνιών

Σεμινάρια Επιμόρφωσης στην τηλεκπαίδευση



Kanaki Z , Voutsina A, Markou A, Pateras I, Potaris K, Avgeris M, Makrythanasis P, Vamvakaris I, Patsea E, Vachlas K, Lianidou E, Georgoulias V, Kotsakis A and Klinakis A, Generation of patient-derived xenografts from non-small cell lung cancer to study tumor heterogeneity (Submitted )

Gkouskou K, Fragiadakis GS, Voutsina A, Alexandraki D. Distinct associations of the Saccharomyces cerevisiae Rad9 protein link Mac1-regulated transcription to DNA repair. Current genetics. 2020;66(3):531-48.

Voutsina A, Fragiadakis GS, Gkouskou K, Alexandraki D. Synergy of Hir1, Ssn6, and Snf2 global regulators is the functional determinant of a Mac1 transcriptional switch in S. cerevisiae copper homeostasis. Current genetics. 2019;65(3):799-816.

Pentheroudakis G, Kotoula V, Koliou GA, Karavasilis V, Samantas E, Aravantinos G, et al. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. Clinical colorectal cancer. 2018;17(4):e631-e7.

Messaritakis I, Stogiannitsi M, Koulouridi A, Sfakianaki M, Voutsina A, Sotiriou A, et al. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PloS one. 2018;13(6):e0197327.

Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, et al. ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment. Clinical cancer research : an official journal of the American Association for Cancer Research. 2018;24(6):1500-10.

Matikas A, Voutsina A, Lagoudaki E, Hatzidaki D, Trypaki M, Stoupis G, et al. Detection of KRAS Exon 2 Mutations in Circulating Tumor Cells Isolated by the ISET System from Patients with RAS Wild Type Metastatic Colorectal Cancer. Translational oncology. 2017;10(4):693-8.

Koinis F, Voutsina A, Kalikaki A, Koutsopoulos A, Lagoudaki E, Tsakalaki E, et al. Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2018;20(2):140-9.

Matikas A, Voutsina A, Trypaki M, Georgoulias V. Role of circulating free DNA in colorectal cancer. World journal of gastrointestinal oncology. 2016;8(12):810-8.

Stratigos M, Matikas A, Voutsina A, Mavroudis D, Georgoulias V. Targeting angiogenesis in small cell lung cancer. Translational lung cancer research. 2016;5(4):389-400.

Kalikaki A, Voutsina A, Koutsopoulos A, Papadaki C, Sfakianaki M, Yachnakis E, et al. ERCC1 SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy. Cancer investigation. 2015;33(4):107-13.

Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, et al. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer. British journal of cancer. 2014;111(9):1757-64.

Kalikaki A, Politaki H, Souglakos J, Apostolaki S, Papadimitraki E, Georgoulia N, et al. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. PloS one. 2014;9(8):e104902.

Saridaki Z, Tzardi M, Sfakianaki M, Papadaki C, Voutsina A, Kalykaki A, et al. BRAFV600E mutation analysis in patients with metastatic colorectal cancer (mCRC) in daily clinical practice: correlations with clinical characteristics, and its impact on patients' outcome. PloS one. 2013;8(12):e84604.

Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, et al. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy. Lung cancer. 2013;82(2):324-9.

Karampeazis A, Voutsina A, Souglakos J, Kentepozidis N, Giassas S, Christofillakis C, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer. 2013;119(15):2754-64.

Saridaki Z, Androulakis N, Vardakis N, Vamvakas L, Kabouraki E, Kalbakis K, et al. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial. British journal of cancer. 2012;107(12):1932-7.

Voutsina A, Tzardi M, Kalikaki A, Zafeiriou Z, Papadimitraki E, Papadakis M, et al. Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2013;26(2):302-13.

Pallis AG, Voutsina A, Kentepozidis N, Giassas S, Papakotoulas P, Agelaki S, et al. A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer. Clinical lung cancer. 2012;13(2):129-35.

Yin M, Yan J, Voutsina A, Tibaldi C, Christiani DC, Heist RS, et al. No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. Lung cancer. 2011;72(3):370-7.

Kalikaki A, Koutsopoulos A, Hatzidaki D, Trypaki M, Kontopodis E, Stathopoulos E, et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung cancer. 2010;69(1):110-5.

Kalikaki A, Kanaki M, Vassalou H, Souglakos J, Voutsina A, Georgoulias V, et al. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. Clinical lung cancer. 2009;10(2):118-23.

Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. British journal of cancer. 2008;99(6):923-9.

Pallis AG, Voutsina A, Kalikaki A, Souglakos J, Briasoulis E, Murray S, et al. 'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer. British journal of cancer. 2007;97(11):1560-6.

27 cited documents in Scopus


870 citations

exclude self ciations 851

14 h-index




  1. Voutsina A., Kalykaki A., Koutsopoulos A., Sfakianaki M., Trypaki M., Tsakalaki E., Agelaki S., Georgoulias V., Mavroudis D.

Next generation sequencing identifies actionable mutations in EGFR-wild type and KRAS mutant non-small cell lung cancer patients

Abstract: #1749; ESMO Congress, 7-11 October 2016, Copenhagen, Denmark

2.      Souglakos, J., Saridaki, Z., Gouges, N., Voutsina, A., Tzardi, M., Kalikaki, A., Sfakianaki, M., Athanasiadis, A., Xynos, E., and Boukovinas, I.

Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG).

Annals of Oncology 27, ii9 (2016)

3.      Kotsakis, A., Voutsina, A., Kalikaki, A., Kentepozidis, N., Koinis, F., Pallis, A., Georgoulias, V.

Long Term Clinical Benefit Of EGFR Wt In Advanced NSCLC Patients Treated For Long Time With Salvage Erlotinib. A Retrospective Analysis.

Journal of Thoracic Oncology (Vol. 10, No. 9, Pp. S410-S411). 360 Park Ave South, New York, NY 10010-1710 USA: Elsevier Science Inc (2015).

4.      Kalikaki, A., Politaki, H., Tzardi, M., Papadimitraki, E., Mavroudis, D., Souglakos, J., Voutsina, A., and Georgoulias, V.

Comparison of KRAS mutation status between primary tumors and circulating tumor cells in patients with metastatic colorectal cancer (mCRC).

Annals of Oncology 24, iv25 (2013)

5.      Voutsina, A., Kalikaki, A., Mitsi, V., Stathopoulos, E., Georgoulias, V., and Mavroudis, D.

Association of PIK3CA kinase domain mutations with poor prognosis in operable breast cancer.

ASCO Meeting Abstracts 29, e21060 (2011)

6.      Voutsina, A., Kalykaki, A., Koutsopoulos, A., Trypaki, M., Stathopoulos, E., Mavroudis, D., and Georgoulias, V.

MET amplification in NSCLC: Correlation with EGFR mutations and gene amplification.

Cancer Research 68, 2169-2169 (2008)

7.      Voutsina, A., Koutsopoulos, A., Kalykaki, A., Souglakos, J., Pallis, A. G., Trypaki, M., Pallis, A., Voutsina, A., Kalikaki, A., Koutsopoulos, A., Souglakos, J., Christophylakis, C., Kentepozidis, N., Giassas, S., Mavroudis, D., and Georgoulias, V.

Correlation of gefitinib efficacy and detection of new EGFR mutation variants in pre-treated patients (pts) with advanced non- small cell lung cancer (NSCLC).

J Clin Oncol: 2007; 25 (June 18s; abstr 18062) (2007)

8.      Voutsina, A., Ampatziadis- Michailidis, Yy., Kalikaki, A., Koutsopoulos, A., Souglakos, J., Pallis, A. G., Trypaki, M., Mavroudis, D., and Georgoulias, V.

EGFR, K-RAS and HER2 mutations as predictive factors for gefitinib sensitivity in non-small cell lung cancer (NSCLC)

EJC Supplements , Volume 5 , Issue 8 , 35 (2007)

9.      Souglakos, J., Mendez, P., Taron, M., Mpoukovinas, I., Queralt, C., Voutsina, A., Papadaki, C., Mavroudis, M., Georgoulias, V., and Rosell, R.

BRCA1 mRNA expression levels are associated with clinical responses to front-line docetaxel/gemcitabine in patients with lung adenocarcinomas in an expanded multicentre phase II study.

EJC Supplements , Volume 5, Issue 8 , 33 (2007).

10.   Pallis, A., Voutsina, A., Kalikaki, A., Koutsopoulos, A., Souglakos, J., Christophylakis, C., Kentepozidis, N., Giassas, S., Mavroudis, D., and Georgoulias, V.

Correlation of gefitinib efficacy and detection of new EGFR mutation variants in pre-treated patients (pts) with advanced non- small cell lung cancer (NSCLC).

J Clin Oncol: 2007; 25 (June 18s; abstr 18062) (2007)

11.   Voutsina, A., Koutsopoulos, A., Kalykaki, A., Souglakos, J., Pallis, A. G., Trypaki, M., Mavroudis, D., and Georgoulias, V.

Novel EGFR mutations in patients with Non Small Cell Lung Cancer (NSCLC) and correlation with sensitivity to gefitinib.

Cancer Research 66, 1195-1195 (2006)

12.   Voutsina, A., Pallis, A. G., Souglakos, J., Koutsopoulos, A., Kalykaki, A., Trypaki, M., Mavroudis, D., and Georgoulias, V.

Epidermal growth factor receptor mutations in Greek gefitinib-treated Non-Small-Cell Lung Cancer (NSCLC) patients.

Annals of Oncology 17, iii42-iii46 (2006)

Αντικείμενα Εξειδίκευσης

Ανατομία (ΕΠΑΛ)Βιολογία ΚυττάρουΓενετική ΒιολογίαΜοριακή ΒιολογίαΥγιεινή (ΕΠΑΛ)

Μοιραστείτε αυτή τη σελίδα

Επικοινωνήστε με τον εκπαιδευτικό

Τύπος μαθήματος

Ιδιαίτερα Μαθήματα

Ξένες Γλώσσες

Δημοτικό Σχολείο

Γυμνάσιο - Λύκειο


Μουσικά Όργανα


Πανελλήνιο Δίκτυο Καθηγητών


Έδρα: Βάκχου 24, Βάρη, Αττική, ΤΚ 16672
Τηλ: 211 800 0071
Ώρες Λειτουργίας: Δευ-Παρ 10:00 έως 17:00
Γραμματεία: info[at]iphestus.com

facebook linkedin twitter instagram

Χρήσιμοι Σύνδεσμοι



Όροι Χρήσης

Εκπαιδευτικό Υλικό

Για εκπαιδευτικούς

Εγγραφή Εκπαιδευτικού

Σύνδεση Μελών

Πίνακας Διαχείρισης Μαθημάτων


Γραφείο Διασύνδεσης

Πληρωμή/Ανανέωση Συνδρομής